

3rd PRESTIGIO Registry meetING on HIV multidrug resistance **ID ECM: 150-471130**

Padua, March 19-20 2026 - Palazzo della Salute

SCIENTIFIC COORDINATORS A. Castagna, M. Santoro, V. Spagnuolo, M. Zazzi

Scientific Rationale

Contemporary antiretroviral therapy (ART) has dramatically improved the prognosis of people living with HIV (PLWH) through the achievement of durable viral suppression and immune function restoration.

However, some heavily treatment-experienced PLWH (HTE-PLWH) are unable to achieve or maintain viral suppression because of HIV-1 multi-drug resistance and/or drug intolerance. For these persons, who are at high risk of clinical progression, morbidity, and mortality, the proper management of the current and future antiretroviral options is critically important. The PRESTIGIO Registry is an observational, prospective, multicenter, annual collection of clinical and virological data and samples HTE-PLWH, regularly followed at several Italian Centers, with documented resistance to the major four classes of antiretroviral drugs (NRTI, NNRTI, PI, INSTI). The aims of the PRESTIGIO Registry include the characterization of this fragile population and the creation of an interactive and multidisciplinary environment to improve the overall management of HTE-PLWH.

The third edition of the PRESTIGIO Registry Meeting (RING) has been conceived from these premises and is a unique opportunity to describe the state of art in the field of HIV multidrug resistance and to discuss the real-life management of HTE-PLWH. Among main topics: Future options for the treatment of HTE PWH; MACE (major adverse cardiovascular events): primary and secondary prevention in HTE PWH; The therapeutic significance of long-term archived resistance mutations; Anal cancer: screening and management.

The RING Meeting is designed as a forum for basic scientists and infectious diseases specialists experienced in HIV drug resistance and management of HTE-PLWH. The RING Meeting includes some key lectures held by experts in the field and plenary discussion groups on challenging clinical experiences. We believe that this format can improve interaction and lively participation and we look forward to seeing you at the RING Meeting!

DAY 1 - Thursday, 19 March 2026

- 14.30 – 14.40** Welcome and Introduction - *A. Castagna, A.M. Cattelan*
- 14.40 – 15.40** The PRESTIGIO Registry: Where Are We? - *V. Spagnuolo*
- Discussion All Steering Committee Members
- 15.40 – 16.10** Lecture: MACE: Primary and Secondary MACE Prevention in HTE PWH – *P. Hsue*
- 16.10 – 16.40** Round Table “Cardiovascular Prevention in HTE PWH: From Evidence to Everyday Practice” - *L. Calza, M. Fabbiani, G. Guaraldi*
- 16.40 – 17.00** *Coffee break in sala*

17.00 – 18.50 Session 1

- Moderators *A. Di Biagio, G.M. Marchetti*
- 17.00 – 18.00** Non-CME accredited - Round Table “Discussion among academy and Pharma representatives”
- 18.00 – 18.30** Round Table: ART 2030 for HTE PWH – *A.M Cattelan, R. Gagliardini, L. Pagnucco, S. Rusconi*
- 18.30 - 18.50** Closing Remarks - *A. Castagna, M. Santoro, V. Spagnuolo, M. Zazzi*

DAY 2 – Friday, 20 March 2026

09.00 – 11.10 Sessione 2

Moderators *L. Comi, M. Santoro*

09.00 – 09.30 Lecture: The Therapeutic Significance of Long-Term Archived Resistance Mutations - *T. Mesplede*

09.30 – 10.00 Round Table "Bringing Archived Resistance into the Clinic: Challenges and Opportunities" – *D. Armenia, A. Giacomelli, F. Saladini*

10.00 – 10.30 News on the Antiretroviral Resistance Profiles of Lenacapavir, Fostemsavir, and Islatravir - *M. Zazzi*

10.30 – 11.10 Round table "Multidrug Resistance Revisited: Do New Drug Classes Change the Rules?" – *G. Cenderello, A. Cervo, M. Santoro*

Coffee break in corso di lavori

11.10 – 16.00 Sessione 3

Moderators *S. Bonora, A. Castagna*

11.10 – 13.00 Going to the RING: Follow-up of Clinical Cases and New Presentations - *G. De Socio, A. De Vito, L. Labate, M. Mena, M. Trizzino*

Discussion all Participants

13.00 – 14.00 *Light Lunch*

14.00 – 14.45 2025–2026 PRESTIGIO Research Proposals - *T. Clemente*

Discussion all Participants

- 14.45 – 15.30** PRESTIGIO Q&A (e-CRF, Biological Samples Collection, Others) - *E. Carini, R. Lolatto*
- 15.30 – 16.00** Take-Home Messages and Closing Remarks - *A. Castagna, M. Santoro, V. Spagnuolo, M. Zazzi*

Acronimi:

ART: antiretroviral therapy

HIV: Human Immunodeficiency Virus

HTE: heavily treatment experienced

INSTI: Integrase Strand Transfer Inhibitor

MACE: major adverse cardiovascular events

NRTI: Nucleoside Reverse Transcriptase T-Inhibitor

NNRTI: Non Nucleoside Reverse Transcriptase T-Inhibitor

PI: fosfatidilinositolo

PLWH: People Living With HIV

PWH: People With HIV

Q&A: Question and Answer

RING: Registry Meeting

Daniele Armenia, Saint Camillus International University of Health Sciences, Roma
Emiliano Bissio, Global Director Medical Affairs, MSD, Madrid
Leonardo Calza, Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi, Bologna
Elisabetta Carini, IRCCS Ospedale San Raffaele, Milano
Antonella Castagna, IRCCS Ospedale San Raffaele, Università Vita - Salute, Milano
Annamaria Cattelan, Azienda Ospedale Università di Padova
Giovanni Cenderello, Azienda Socio Sanitaria Ligure 1, Sanremo (IM)
Adriana Cervo, Azienda Ospedaliero-Universitaria Policlinico di Modena
Tommaso Clemente, IRCCS Ospedale San Raffaele Università Vita - Salute, Milano
Laura Comi, ASST Papa Giovanni XXIII, Bergamo
Giuseppe Vittorio Luigi De Socio, Azienda Ospedaliera di Perugia
Andrea De Vito, Azienda Ospedaliero Universitaria di Sassari
Antonio Di Biagio, AOU Metropolitana Genova IRCCS, DiSSal, Università di Genova
Massimiliano Fabbiani, Azienda Ospedaliero-Universitaria Senese - Università degli Studi di Siena
Roberta Gagliardini, INMI Lazzaro Spallanzani IRCCS, Roma
Andrea Giacomelli, ASST Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano
Giovanni Guaraldi, Azienda Ospedaliero - Universitaria Policlinico di Modena, Università degli Studi di Modena, e Reggio Emilia, Modena
Priscilla Hsue, University of California, David Geffen School of Medicine, Los Angeles
Laura Labate, IRCCS Ospedale San Martino, Genova
Riccardo Lolatto, IRCCS Ospedale San Raffaele, Milano
Giulia Carla Marchetti, ASST Santi Paolo e Carlo, Università degli Studi di Milano
Maurizio Mena, Azienda Ospedaliera "Ospedale Civile di Legnano" - ASST Ovest Milanese, Legnano
Thinault Mesplede, Erasmus University Medical Center, Rotterdam
Ana Milinkovic, Senior Global Medical Director, ViiV Healthcare
Layla Pagnucco, Fondazione IRCCS Policlinico San Matteo, Pavia
Stefano Rusconi, ASST Ovest Milanese - DIBIC, Università degli Studi di Milano
Francesco Saladini, Università degli Studi di Siena
Maria Santoro, Università degli Studi di Roma Tor Vergata, Roma
Vincenzo Spagnuolo, IRCCS Ospedale San Raffaele, Università Vita-Salute, Milano
Marcello Trizzino, Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone", Palermo
Maurizio Zazzi, Università degli Studi di Siena

Tutti i CV dei docenti sono disponibili sul sito: makeevent.it/upload/events/0988/curriculum.pdf